Please provide your email address to receive an email when new articles are posted on . Levonorgestrel-releasing intrauterine system users vs. nonusers had an increased risk for breast cancer. Breast ...
Please provide your email address to receive an email when new articles are posted on . Treatment success for the JADA system was high for both vaginal and cesarean births. Overall, 2.8% of women in ...
The FDA gave premarket approval to the first medical device for the treatment of women with symptomatic moderate-to-severe intrauterine adhesions, known as Asherman syndrome, maker Womed announced on ...
The study was a multicentre, double-blind, randomised, placebo-controlled trial of mepivacaine (10 mL of 20 mg/mL) vs placebo (0.9 mg/mL sodium chloride) instilled into the uterus 2 minutes before IUD ...
A study led by obstetricians has shown that a new device can rapidly control postpartum hemorrhage, a major cause of severe maternal morbidity and death, in a wide range of patients. A study led by ...
Bizcommunity on MSN
Pharma Dynamics launches South Africa’s first generic hormonal IUD
Pharma Dynamics has entered the medical device market following the introduction of South Africa’s first generic hormone-releasing intrauterine device (IUD). The generic 52mg levonorgestrel IUD ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results